Genetic Testing Market - Global Forecast 2025-2032

Genetic testing is driving significant change in healthcare by enabling earlier diagnoses, personalized treatment pathways, and data-driven decision-making across clinical and consumer settings. For industry leaders, understanding the evolving landscape is essential for maintaining competitiveness as innovation and regulatory shifts redefine global markets.

Market Snapshot: The Genetic Testing Market

The genetic testing market grew from USD 13.55 billion in 2024 to USD 15.44 billion in 2025, with robust annual growth expected at a compound annual growth rate (CAGR) of 14.38%, projecting the market to reach USD 39.72 billion by 2032.

Scope & Segmentation of the Genetic Testing Market

This market research provides an in-depth analysis across multiple structural layers and regional perspectives. Segments covered include:

• Product: Consumables & Equipment; Software & Services
• Test Type: Carrier Testing; Diagnostic Testing; New Born Screening; Pharmacogenomics; Preimplantation Testing; Prenatal Testing; Presymptomatic & Predictive Testing
• Technology: Cytogenetics; DNA Sequencing; Gene Expression Profiling; Microarrays; PCR
• Application: Autoimmune Disorders; Cancer; Chronic Diseases; Genetic Disorders; Neurodegenerative Diseases
• Distribution Channel: Offline; Online
• End-User: Diagnostic Laboratories; Home Setting; Hospitals & Clinics
• Region: Americas (North America, Latin America); Europe, Middle East & Africa (Europe, Middle East, Africa); Asia-Pacific
• Companies Analyzed: Abbott Laboratories; Agilent Technologies, Inc.; Becton, Dickinson and Company; Bio-Rad Laboratories, Inc.; Bio-Techne Corporation; Bruker Corporation; Centogene N.V.; Color Health, Inc.; CooperSurgical Inc.; Editas Medicine, Inc.; Eugene Labs Pty Ltd.; Eurofins Scientific SE; F. Hoffmann-La Roche AG; Fulgent Genetics, Inc.; Gene by Gene, Ltd.; GeneDx, LLC; Illumina, Inc.; Invitae Corporation; Laboratory Corporation of America Holdings; Living DNA Ltd.; Macrogen, Inc.; MyHeritage Ltd.; Myriad Genetics, Inc.; Natera, Inc.; Newtopia Inc.; PathogenDx Corporation; PerkinElmer Inc.; Qiagen N.V.; Quest Diagnostics Incorporated; Sanofi S.A.; Thermo Fisher Scientific Inc.

Key Takeaways for Senior Decision-Makers

• Integration of genetic data into clinical care enhances patient outcomes, offering tailored therapeutic strategies and earlier disease detection across primary healthcare settings.
• Adoption of artificial intelligence and advanced automation accelerates test development cycles, improves diagnostic accuracy, and scales laboratory operations to keep pace with emerging biomarker discoveries.
• Market expansion is supported by harmonized regulations, evolving reimbursement models, and growing public awareness driven by direct-to-consumer testing and digital health platforms.
• Diversified partnerships across diagnostics, tech sectors, and pharmaceutical companies foster rapid innovation, integrated offerings, and strengthened supply chain resilience.
• Consumer expectations for privacy and user experience are shaping industry strategies, with emphasis on secure data management and accessible testing solutions beyond traditional clinic settings.

Tariff Impact and Supply Chain Implications

Recent United States tariffs on imported laboratory consumables, equipment components, and critical reagents have directly influenced cost structures and operational decision-making for providers and suppliers. Laboratories are responding by diversifying procurement strategies, engaging domestic suppliers, and optimizing logistics to offset increased expenses and maintain service accessibility.

Trade compliance complexity has intensified, prompting investment in dedicated teams and process automation. These adjustments are both a short-term challenge and a catalyst for building resilient supply chains and regional manufacturing partnerships.

Methodology & Data Sources

This analysis combines primary interviews with industry experts, laboratory leaders, and executive stakeholders alongside review of peer-reviewed literature, regulatory documents, and structured surveys. Trade and import-export data, alongside scenario analysis, support a balanced market view and reliable forecast integrity.

Why This Report Matters for Executive Teams

• Enables informed strategy by detailing actionable market trends and innovation pathways in genetic testing.
• Empowers benchmarking against regional regulations, technology adoption rates, and supply chain adaptability to anticipate future shifts.

Conclusion

Genetic testing is rapidly transforming healthcare value chains, requiring agile strategies and collaborative innovation. Stakeholders positioned for change will drive adoption and realize sustained market advantage as technologies and regional dynamics evolve.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.